Crizotinb or Standard Chemotherapy in Met Exon 14 Skipping Advanced NSCLC
This study aims to explore the efficacy and safety of Crizotinb or Standard Chemotherapy in Met exon 14 skipping Advanced Non-small Cell Lung Cancer
Non-small Cell Lung Cancer
DRUG: Crizotinib|DRUG: Pemetrexed
Progression-free survival (PFS), PFS defines as first dose to first documented disease progression assessed by investigator or death due to any cause, Time from first subject dose to study completion, or up to 36 month
Overall survival (OS), To assess overall survival, define as first dose to the death of the subject due to any cause, Time from first subject dose to study completion, or up to 36 month|Objective Response Rate (ORR), To assess Chemotherapy and TKIs overall response rate according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 by investigator, define as the proportion of subjects who have a complete response (CR) or a partial response (PR), Time from first subject dose to study completion, or up to 36 month
This study aims to explore the efficacy and safety of Crizotinb or Standard Chemotherapy in Met exon 14 skipping Advanced Non-small Cell Lung Cancer . All the clinical and survival data will be collected for full analysis.